Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome

European Journal of Pain

Volumn 2, Issue 2, 1998, Pages 133-142

  Andersson, M ^a   Bagby, J R ^a   Dyrehag, L E ^a,b   Gottfries, C G ^b  

^a Kungälv Hospital   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

STAPHYLOCOCCUS TOXOID; STAPHYLOCOCCUS VACCINE; STAPHYPAN BERNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBROMYALGIA; HUMAN; NEUROIMMUNOLOGY; NEUROMODULATION; PAIN ASSESSMENT; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0031873897     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3801(98)90006-4     Document Type: Article

References (38)

1. Åsberg M, Montgomery SA, Perris C, Shalling D, Sedvall GA. A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978; Suppl. 271: 5-27.
2. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with fibromyalgia syndrome. Arthritis Rheum 1992; 32: 454-460.
3. Bengtsson A, Henriksson KG, Jorfeldt L, Kagedal B, Lennmarken C, Lindström F. Primary fibromyalgia. A clinical and laboratory study of 55 patients. Scand J Rheumatol 1986; 15: 340-347.
4. Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kikinis R, Jolesz FA, Folks T, Balachandran N, Peter JB, Gallo RC, Komaroff AL. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116: 103-113.
5. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities. Arch Intern Med 1994; 154: 2049-2053.
6. Buskila D, Press J, Gedalia A. et al. Assessment of non-articular tenderness and prevalence of fibromyalgia in children. J Rheumatol 1993; 20: 368-370.
7. Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg IJ. An association of membrane damaging toxins from coagulase negative staphylococcus and chronic orofacial muscle pain. J Med Microbiol, accepted.
8. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985; 12: 980-983.
9. 12 levels. Ann Intern Med 1996; 299-304.
10. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-959.
11. Goldenberg DL. A review of the pharmacologic treatment of fibromyalgia and myofascial pain. In: Værøy H, Merskey H, editors, Progress in Fibromyalgia and Myofascial Pain. Amsterdam: Elsevier Science Publishers B.V., 1993; 361-367.
12. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Clinical Global Impressions (028-CGI). Washington, DC: USGPO, 1976: 216-222.
13. Hilden J. Fibromyalgidiagnosen. En kritisk oversigt over nordisk litteratur. Nord Med 1996; 111: 308-312.
14. Holmes GP, Kaplan JE, Gantz NM. et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387-389.
15. Jacobsen S. Chronic Widespread Musculoskeletal Pain - the Fibromyalgia Syndrome. Doctoral thesis. Copenhagen: Lægeforeningens forlag, 1994.
16. Klein R, Bänsch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology 1992; 17: 593-598.
17. Knave B, Mindus P, Struwe G. Neurasthenic symptoms in workers occupationally exposed to jet fuel. Acta Psychiatr Scand 1979; 60: 39-49.
18. Landey A, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome clinical condition associated with immune activation. Lancet 1991; 338: 707-712.
19. Lindman R, Hagberg M, Bengtsson A, Henriksson KG, Thornell L-E. Capillary structure and mitochondrial volume density in the trapezius muscle of chronic trapezius myalgia, fibromyalgia and healthy subjects. J Musculoskel Pain 1995; 3: 5-22.
20. Lloyd AR, Hickie I, Baughton CR, Spencer O, Wakefield D. Prevalence of chronic fatigue syndrome in an Australian population. Med J Austr 1990; 53: 522-528.
21. Lorenzen I. Fibromyalgia: A clinical challenge. J Intern Med 1994; 235: 697-709.
22. Masi AT, Yunus MB. Fibromyalgia - which is the best treatment? A personalized, comprehensive, ambulatory, patient-involved management programme. Balliere's Clin Rheum 1990; 4: 333-370.
23. McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training programme on the manifestation of primary fibromyalgia. Arthritis Rheum 1988; 31: 1135-1141.
24. McGregor N, Butt HL, Zerbes M, Klineberg IJ, Dunstan RH, Roberts TK. Assessment of pain (distribution & onset), symptoms, SCL-90-R inventory responses and the association with infectious events in patients with chronic orofacial pain. J Orofacial Pain 1997; 10: 339-350.
25. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, CNS serotonin and pain. In: Chrichley M, Friedman A, editors. Headache: Physiopathological and Clinical Concepts. New York: Raven Press, 1982; 51-57 (Adv Neurol, 33).
26. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, CNS serotonin and pain. In: Chrichley M, Friedman A, editors. Headache: Physiopathological and Clinical Concepts. New York: Raven Press, 1982; 51-57 (Adv Neurol, 33).
27. Regland B, Andersson M, Abrahamsson L, Bagby J, Dyrehag L-E, Gottfries C-G. Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand J Rheumatol 1997; 26: 301-307.
28. Russel IJ. Biochemical abnormalities in fibromyalgia syndrome. J Musculoskeletal Pain 1994; 2: 101-115.
29. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991; 18: 1558-1563.
30. Simons DG. Muscle pain syndromes - part 1. Am J Phys Med 1975; 54: 289-311.
31. Smythe HA. Non-articular rheumatism and psychogenic musculoskeletal syndromes. In: McCarthy DJ, editor, Arthritis and Allied Conditions, 9th edn. Philadelphia, PA: Lea and Febiger, 1979; 881-891.
32. Sörensen J, Bengtsson A, Bäckman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Scand J Rheumatol 1995; 24: 360-365.
33. Wilson A, Hickie I, Hadzi-Pavlovic D, Boughton C, Dwyer J, Wakefield D. Longitudinal study of outcome of chronic fatigue syndrome. Br Med J 1994; 308: 756-759.
34. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia; report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-172.
35. Wolfe F, Ross K, Anderson J, Russell IJ. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1993; 36: 57.
36. Yunus MB, Masi AT, Calabro JJ, Miller K, Feigenbaum S. Primary fibromyalgia (fibrositis): A clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981; 11: 151-171.
37. Yunus M. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846-850.
38. Zung WWK. A self rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70.